Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective

Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations

Volumn , Issue , 2011, Pages 37-56

  Wadhwa, Meenu ^a   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Antibody detection assays, screening conventional approaches, ELISAs, radioimmunoprecipitation assays; Assay validation, immunogenicity assessment being fit for purpose, reliable and robust; Guidance, immunogenicity assessment biologically derived therapeutic proteins, European perspective

Indexed keywords

EID: 84871439652     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075685.ch3     Document Type: Chapter

References (48)

1. European Medicines Agency . ( 2007 ). Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process . Non-clinical and clinical issues. Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/10169506enfin.pdf.
2. European Medicines Agency . ( 2005 ). Guideline on similar biological medicinal products . Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/043704en.pdf.
3. European Medicines Agency . ( 2006 ). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues . Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/4934805en.pdf.
4. European Medicines Agency . ( 2006 ). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues . Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/4283205en.pdf.
5. Bertolotto, A. ( 2004 ). Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis . Curr Opin Neurol, 17, 241-246 .
6. Waters, B., Lillicrap, D. ( 2009 ). The molecular mechanisms of immunomodulation and tolerance induction to factor VIII . J Thromb Haemost, 7 ( 9 ), 1446-1456 .
7. Wang, J., Lozier, J., Johnson, G., Kirshner, S., Verthelyi, D., Pariser, A., Shores, E., Rosenberg, A. ( 2008 ). Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment . Nature Biotechnol, 26 ( 8 ), 901-908 .
8. Baert, F., Noman, M., Vermiere, S., Van Assche, G., D'Haens, G., Carbonez, A., Rutgeerts, P. ( 2003 ). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn ' s disease . N Engl J Med, 348, 601-608 .
9. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. ( 2001 ). Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood, 98, 3241-3248 .
10. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., Mayeux, P. ( 2002 ). Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin . N Engl J Med, 346, 469-475 .
11. European Medicines Agency . ( 2007 ). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins . Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/1432706en.pdf.
12. European Medicines Agency . ( 2009 ). Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use has been released for consultation . Available at http://www.EMEA.europa.eu/pdfs/human/biosimilar/11472009en.pdf.
13. Food and Drug Administration (FDA) . ( 2009 ). Guidance for industry. Assay development for immunogenicity testing of therapeutic proteins . Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.
14. Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., Zuckerman, L.A. ( 2004 ). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products . J Immunol Methods, 289, 1-16 .
15. Gupta, S., Indelicato, S.R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A.R., Richards, S.M., Rup, B., Shores, E., Swanson, S.J., Wakshull, E. ( 2007 ). Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics . J Immunol Methods, 321, 1-18 .
16. Shankar, G., Devanarayan, V., Amaravadi, L., et al. ( 2008 ). Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products . J Pharm Biomed Anal, 48 ( 5 ), 1267-1281 .
17. Koren, E., Smith, H.W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y.C., Devanarayan, V., Gorovits, B., Gupta, S., Parish, T., Quarmby, V., Moxness, M., Swanson, S.J., Taniguchi, G., Zuckerman, L.A., Stebbins, C.C., Mire-Sluis, A. ( 2008 ). Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products . J Immunol Methods, 333 ( 1-2 ), 1-9 .
18. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., Thomsen, O.ø., Hanauer, S.B., McColm, J., Bloomfield, R., Sandborn, W.J. ( 2007 ). Maintenance therapy with certolizumab pegol for Crohn ' s disease . N Engl J Med, 357, 239-250 .
19. Van Walle, I., Gansemans, Y., Parren, P.W., Stas, P., Lasters, I. ( 2007 ). Immunogenicity screening in protein drug development . Expert Opin Biol Ther, 7, 405-418 .
20. European Medicines Agency . ( 2008 ). European public assessment report (EPAR) for Remicade ® . Available at http://www.EMEA.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm.
21. Hermeling, S., Aranha, L., Damen, J., Slijper, M., Schellekens, H., Crommelin, D., Jiskoot, W. ( 2005 ). Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b . Pharm Res, 22, 1997-2006 .
22. van Beers, M.M., Sauerborn, M., Gilli, F., Hermeling, S., Brinks, V., Schellekens, H., Jiskoot, W. ( 2010 ). Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta . J Immunol Methods, 352 ( 1-2 ), 32-37 .
23. De Groot, A.S., Moise, L., McMurry, J.A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D.W., Martin, W. ( 2008 ). Activation of natural regulatory T cells by IgG Fc-derived peptide " Tregitopes . " Blood, 112 ( 8 ), 3303-3311 .
24. Shankar, G., Pendley, C., Stein, K.E. ( 2007 ). A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs . Nature Biotechnol, 25, 555-561 .
25. Gross, J., Moller, R., Henke, W., Hoesel, W. ( 2006 ). Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO . J Immunol Methods, 313, 176-182 .
26. Tacey, R., Greway, A., Smiell, J., Power, D., Kromminga, A., Daha, M., Casadevall, N., Kelley, M. ( 2003 ). The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay . J Immunol Methods, 283, 317-329 .
27. Thorpe, R., Swanson, S.J. ( 2005 ). Current methods for detecting antibodies against erythropoietin and other recombinant proteins . Clin Diagn Lab Immunol, 12, 28-39 .
28. Moxness, M., Tatarewicz, S., Weeraratne, D., Murakami, N., Wullner, D., Mytych, D., Jawa, V., Koren, E., Swanson, S.J. ( 2005 ). Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies . Clin Chem, 51, 1983-1985 .
29. Wadhwa, M., Thorpe, R. ( 2006 ). Strategies and assays for the assessment of unwanted immunogenicity . J Immunotoxicol, 3, 115-121 .
30. Aarden, L., Ruuls, S.R., Wolbink, G. ( 2008 ). Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement . Curr Opin Immunol, 20 ( 4 ), 431-435 .
31. Bartelds, G.M., Wijbrandts, C.A., Nurmohamed, M.T., Stapel, S., Lems, W.F., Aarden, L., Dijkmans, B.A.C., Tak, P.P., Wolbink, G.J. ( 2007 ). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis . Ann Rheum Dis, 66, 921-926 .
32. Lofgren, J.A., Dhandapani, S., Pennucci, J.J., Abbott . C.M., Mytych, D.T., Kaliyaperumal, A., Swanson, S.J., Mullenix, M.C. ( 2007 ). Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab . J Immunol, 178, 7467-7772 .
33. Wadhwa, M., Skog, A.-L.H., Bird, C., Ragnhammar, P., Lilljefors, M., Gaines-Das, R., Mellstedt, H., Thorpe, R. ( 1999 ). Immunogenicity of granulocyte-macrophage colony stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF . Clin Can Res, 5, 1353-1361 .
34. Wadhwa, M., Bird, C., Fagerberg, J., Gaines-Das, R., Ragnhammar, P., Mellstedt, H., Thorpe, R. ( 1996 ). Production of neutralizing GM-CSF antibodies in carcinoma patients following GM-CSF combination therapy . Clin Exp Immunol, 104, 351-358 .
35. Subramanyam, M. ( 2008 ). Case study: immunogenicity of natalizumab . In Biotechnology: Pharmaceutical Aspects, Vol VIII . Immunogenicity of Biopharmaceuticals . van der Weert M, Moller EH, eds. Springer, New York ; AAPS Press .
36. Wei, X., Swanson, S.J., Gupta, S. ( 2004 ). Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies . J Immunol Methods, 293, 115-126 .
37. Bertolotto, A., Sala, A., Caldano, M., Capobianco, M., Malucchi, S., Marnetto, F., Gilli, D. ( 2007 ). Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta . J Immunol Methods, 321 ( 1-2 ), 19-31 .
38. Hu, J., Gupta, S., Swanson, S.J., Zhuang, Y. ( 2009 ). A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum . J Immunol Methods, 345 ( 1-2 ), 70-79 .
39. Kelley, M., Cooper, C., Matticoli, A., Greway, A. ( 2005 ). The detection of anti-erythropoietin antibodies in human serum and plasma. Part II. Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies . J Immunol Methods, 300, 179-191 .
40. Moore, M., Meager, A., Wadhwa, M., Burns, C. ( 2009 ). Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type I interferon-inducible 6-16 mRNA . J Pharm Biomed Anal, 49, 534-539 .
41. Lallemand, C.J., Meritet, F., Erickson, R., Grossberg, S.E., Roullet, E., Lyon-Caen, O., et al. ( 2008 ). Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene . J Interferon Cytokine Res, 28, 393-404 .
42. Baltrukonis, D., Finco-Kent, D., Poirier, M., LeSauteur, L., Kawabata, K. ( 2006 ). Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870893 . J Immunotoxicol, 3, 157-164 .
43. Klakamp, S.L., Lu, H., Tabrizi, M., Funelas, C., Roskos, L.K., Coleman, D. ( 2007 ). Application of analytical detection concepts to immunogenicity testing . Anal Chem, 79, 8176-8184 .
44. Zwieg, M.H., Campbell, G. ( 1993 ). Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine . Clin Chem, 39, 561-577 .
45. Patton, A., Mullenix, M.C., Swanson, S.J., Koren, E. ( 2005 ). An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen . J Immunol Methods, 304, 189-195 .
46. Bourdage, J.S., Cook, C.A., Farrington, D.L., Chain, J.S., Konrad, R.J. ( 2007 ). An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug . J Immunol Methods, 327, 10-17 .
47. Sickert, D., Kroeger, K., Zickler, C., Chokote, E., Winkler, B., Grenet, J.M., Legay, F., Zaar, A. ( 2008 ). Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore . J Immunol Methods, 334 ( 1-2 ), 29-36 .
48. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., Murphy, B.A., Satinover, S.M., Hosen, J., Mauro, D., Slebos, R.J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D.J., Platts-Mills, T.A. ( 2008 ). Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose . N Engl J Med, 358 ( 11 ), 1109-1117 .